IDS-C30

Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial

In a secondary analysis of ESCAPE-TRD (n=636), esketamine nasal spray plus an oral antidepressant, dosed according to US prescribing information, produced significantly higher remission rates from week 8 to week 32 and greater, earlier reductions in MADRS scores (from day 8) than quetiapine XR, with fewer discontinuations due to adverse events.

Published

January 17, 2025

Journal

CNS Spectrums

Authors

McIntyre, R. S., Mattingly, G., Godinov, Y., Buyze, J., Turkoz, I., Cabrera, P., Patel, M., Martinez, L., Himedan, M., Lopena, O.